Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCl2A1 as critical target genes

Journal of Clinical Investigation

Volumn 116, Issue 12, 2006, Pages 3171-3182

  Piva, Roberto ^a   Pellegrino, Elisa ^a   Mattioli, Michela ^b   Agnelli, Luca ^b   Lombardi, Luigia ^b   Boccalatte, Francesco ^a   Costa, Giulia ^a   Ruggeri, Bruce A ^c   Cheng, Mangeng ^c   Chiarle, Roberto ^a   Palestro, Giorgio ^a   Neri, Antonino ^b   Inghirami, Giorgio ^a,d  

^a UNIVERSITY OF TURIN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c CEPHALON INC   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CCAAT ENHANCER BINDING PROTEIN BETA; CHIMERIC PROTEIN; NUCLEOPLASMIN; PROTEIN BCL 2;

ARTICLE; CELL GROWTH; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; VALIDATION PROCESS;

ANIMALS; APOPTOSIS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL CYCLE; CELL LINE; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE-CELL; MICE; NEOPLASMS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 33845298261     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI29401     Document Type: Article

References (51)

1. Morris, S.W., et al. 1994. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 263:1281-1284.
2. Duyster, J., Bai, R.Y., and Morris, S.W. 2001. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 20:5623-5637.
3. Kutok, J.L., and Aster, J.C. 2002. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J. Clin. Oncol. 20:3691-3702.
4. Pulford, K., Morris, S.W., and Turturro, F. 2004. Anaplastic lymphoma kinase proteins in growth control and cancer. J. Cell. Physiol. 199:330-358.
5. Lamant, L., et al. 2000. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am. J. Pathol. 156:1711-1721.
6. Cessna, M.H., et al. 2002. Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 cases. Mod. Pathol. 15:931-938.
7. Lu, K.V., et al. 2005. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J. Biol. Chem. 280:26953-26964.
8. Morris, S.W., et al. 1997. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 14:2175-2188.
9. Iwahara, T., et al. 1997. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 14:439-449.
10. Chiarle, R., et al. 2003. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 101:1919-1927.
11. Piva, R., et al. 2006. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood. 107:689-697.
12. Wan, W., et al. 2006. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood. 107:1617-1623.
13. Ambrogio, C., et al. 2005. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 106:3907-3916.
14. Zamo, A., et al. 2002. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 21:1038-1047.
15. Slupianek, A., et al. 2001. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 61:2194-2199.
16. Wellmann, A., et al. 1997. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. FASEB J. 11:965-972.
17. Chiarle, R., et al. 2005. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11:623-629.
18. Rassidakis, G.Z., et al. 2005. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood. 105:827-829.
19. Bai, R.Y., Dieter, P., Peschel, C., Morris, S.W., and Duyster, J. 1998. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol. Cell. Biol. 18:6951-6961.
20. Villalva, C., et al. 2002. Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma. Br. J. Haematol. 118:791-798.
21. Wellmann, A., et al. 2000. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 96:398-404.
22. Rust, R., et al. 2005. High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma. J. Clin. Pathol. 58:520-524.
23. Willenbrock, K., et al. 2006. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica. 91:596-604.
24. Watanabe, M., et al. 2005. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res. 65:7628-7634.
25. Schadt, E.E., Li, C., Ellis, B., and Wong, W.H. 2001. Feature extraction and normalization algorithms for high-density oligonucleotide gene expression array data. J. Cell. Biochem. Suppl. 37:120-125.
26. Mandal, M., et al. 2005. The BCL2A1 gene as a pre- T cell receptor-induced regulator of thymocyte survival. J. Exp. Med. 201:603-614.
27. Ferrando, A.A., et al. 2002. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1:75-87.
28. Ramji, D.P., and Foka, P. 2002. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J. 365:561-575.
29. Jundt, F., et al. 2005. A rapamycin derivative (everolimus) controls proliferation through downregulation of truncated CCAAT enhancer binding protein beta and NF-kappaB activity in Hodgkin and anaplastic large cell lymphomas. Blood. 106:1801-1807.
30. Quintanilla-Martinez, L., et al. 2006. NPM-ALK dependent expression of the transcription factor CCAAT/enhancer binding protein (C/EBP)beta in Alk-positive anaplastic large cell lymphomas. Blood. 108:2029-2036.
31. Pulford, K., et al. 2004. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell. Mol. Life Sci. 61:2939-2953.
32. Jackson, A.L., et al. 2003. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21:635-637.
33. Yamamoto, A., Cremona, M.L., and Rothman, J.E. 2006. Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J. Cell Biol. 172:719-731.
34. Kolfschoten, I.G., et al. 2005. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell. 121:849-858.
35. Ngo, V.N., et al. 2006. A loss-of-function RNA interference screen for molecular targets in cancer. Nature. 441:106-110.
36. Westbrook, T.F., et al. 2005. A genetic screen for candidate tumor suppressors identifies REST. Cell. 121:837-848.
37. Moffat, J., et al. 2006. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 124:1283-1298.
38. Tomayko, M.M., et al. 1999. Expression of the Bcl-2 family member A1 is developmentally regulated in T cells. Int. Immunol. 11:1753-1761.
39. Mahadevan, D., et al. 2005. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol. Cancer Ther. 4:1867-1879.
40. Morales, A.A., et al. 2005. High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int. J. Cancer. 113:730-737.
41. Greenbaum, L.E., et al. 1998. CCAAT enhancer-binding protein β is required for normal hepatocyte proliferation in mice after partial hepatectomy. J. Clin. Invest. 102:996-1007.
42. Zhu, S., Yoon, K., Sterneck, E., Johnson, P.F., and Smart, R.C. 2002. CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc. Natl. Acad. Sci. U. S. A. 99:207-212.
43. Buck, M., Poli, V., Hunter, T., and Chojkier, M. 2001. C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. Mol. Cell. 8:807-816.
44. Zahnow, C.A. 2002. CCAAT/enhancer binding proteins in normal mammary development and breast cancer. Breast Cancer Res. 4:113-121.
45. Lamb, J., et al. 2003. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 114:323-334.
46. Smith, R., et al. 2006. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell. 9:405-416.
47. Wiznerowicz, M., and Trono, D. 2003. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 77:8957-8961.
48. Piva, R., et al. 2005. 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins. Blood. 105:1750-1758.
49. Mattioli, M., et al. 2005. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene. 24:2461-2473.
50. Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95:14863-14868.
51. Jagasia, M., et al. 2004. Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant. Leuk. Lymphoma. 45:2261-2267.